Immunotherapy with high-dose IL-2 had been the mainstay of systemic treatment for advanced renal cell carcinoma until the development of agents inhibiting the VEGF and mTOR pathways. The gene discussed is VEGFA; the disease is hereditary clear cell renal cell carcinoma.